die(' Site is under construction

Dear site users

Site is under construction.

The site will be ready in less than 24 hours.

We are sorry for the inconvenience.

www.yektaweb.com

'); Reports of Biochemistry and Molecular Biology rbmb.net Basic Sciences http://rbmb.net 1 admin 2322-3480 2322-3480 10.61882/rbmb en jalali 1402 5 1 gregorian 2023 8 1 12 2 online 1 fulltext
en The Ratio of Cysteine-Rich Angiogenic Inducer 61 to MicroRNA -155 Expression as a Preeclampsia Diagnostic Marker and Predictor of Its Severity بیوشیمی Biochemistry مقالات اصلی Original Article <div style="text-align: justify;"><span style="font-size:10pt"><span style="text-justify:kashida"><span style="text-kashida:0%"><span style="line-height:normal"><span style="tab-stops:396.55pt"><span style="font-family:Calibri,sans-serif"><b><i><span lang="EN-GB" style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.3pt">Background:</span></span></span></span></i></b> <span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.3pt">Preeclampsia (PE) is a multisystem pregnancy disorder that increases maternal-perinatal morbidity and mortality significantly. MicroRNA-155 (miR-155) overexpression in the sera of pregnant women has been linked to preeclampsia. Researchers discovered that miR-155 acts during pregnancy by down-regulating and reducing the cysteine-rich angiogenic inducer 61 (CYR61), which causes local ischemia as well as oxidative stress.</span></span></span></span></span></span></span></span></span></span><br> <br> <span style="font-size:10pt"><span style="text-justify:kashida"><span style="text-kashida:0%"><span style="line-height:normal"><span style="tab-stops:396.55pt"><span style="font-family:Calibri,sans-serif"><b><i><span lang="EN-GB" style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.3pt">Methods:</span></span></span></span></i></b><b> </b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.3pt">The level of miR-155 expression in all serum samples was quantified using real-time polymerase chain reaction (RT-PCR), and serum CYR61 was measured using enzyme-linked immunosorbent assays. Together with the Cyr-61/miR-155 ratio, they were evaluated as biomarkers for PE pathogenesis and severity prediction.</span></span></span></span></span></span></span></span></span></span><br> <br> <span style="font-size:10pt"><span style="text-justify:kashida"><span style="text-kashida:0%"><span style="line-height:normal"><span style="tab-stops:396.55pt"><span style="font-family:Calibri,sans-serif"><b><i><span lang="EN-GB" style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.3pt">Results:</span></span></span></span></i></b><b> </b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.3pt">MiR-155 expression, serum CYR61 levels, and Cyr-61/miR-155 ratios were all significantly higher in PE patients compared to the control group. Serum CYR61 levels and the Cyr-61/miR-155 ratio differed significantly between mild and severe PE patients.</span></span></span></span></span></span></span></span></span></span><br> <br> <span style="font-size:10pt"><span style="text-justify:kashida"><span style="text-kashida:0%"><span style="line-height:normal"><span style="tab-stops:396.55pt"><span style="font-family:Calibri,sans-serif"><b><i><span lang="EN-GB" style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.3pt">Conclusion:</span></span></span></span></i></b><b> </b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.3pt">MiR-155 expression, serum CYR61 levels, and Cyr-61/miR-155 may serve as biomarkers for PE pathogenesis and severity prediction.</span></span></span></span></span></span></span></span></span></span></div> <quillbot-extension-portal></quillbot-extension-portal><quillbot-extension-portal></quillbot-extension-portal><quillbot-extension-portal></quillbot-extension-portal> Biomarker, Cysteine-Rich Protein 61, MicroRNAs, Pre-Eclampsia. 332 339 http://rbmb.net/browse.php?a_code=A-10-1249-1&slc_lang=en&sid=1 Sarah Mamdouh Shoeib 100319475328460017978 100319475328460017978 No Clinical pathology department, Faculty of Medicine, Tanta University, Egypt. Doaa Elwy Abdeldaim 100319475328460017979 100319475328460017979 No Public Health Department, Faculty of Medicine, Tanta University, Tanta. Shimaa Samir Mashal 100319475328460017980 100319475328460017980 No Internal Medicine department, Faculty of Medicine, Tanta University, Egypt. Rowida Raafat Ibrahim owaida.yousef@med.tanta.edu.eg 100319475328460017981 100319475328460017981 Yes Medical Biochemistry & Molecular Biology Department, Faculty of Medicine, Tanta University, Egypt. Lamees Mohamed Dawood 100319475328460017982 100319475328460017982 No Medical Biochemistry & Molecular Biology Department, Faculty of Medicine, Tanta University, Egypt. Doaa Shatat 100319475328460017983 100319475328460017983 No Gynecology and Obstetrics Department, Faculty of Medicine, Tanta University, Egypt. Yasmine Ibrahim El-Masry 100319475328460017984 100319475328460017984 No Gynecology and Obstetrics Department, Faculty of Medicine, Tanta University, Egypt. Ahmed Almeldin 100319475328460017985 100319475328460017985 No Physiology Department, Faculty of Medicine, Tanta University, Tanta, Egypt. Radwa Mahamoud El Sharaby 100319475328460017986 100319475328460017986 No Clinical pathology department, Faculty of Medicine, Tanta University, Egypt.